{"ResultsReport": {"xmlns": "http://integration.foundationmedicine.com/reporting", "xmlnsxsi": "http://www.w3.org/2001/XMLSchema_instance", "xsischemaLocation": "http://integration.foundationmedicine.com/reporting http://integration.foundationmedicine.com/reporting/ResultsReport.2.1.xsd", "CustomerInformation": {"ReferenceID": "01_2021_00017160", "CSN": null, "TRF": "ORD_1240190_01", "MRN": "47543986", "PhysicianId": "16468", "NPI": "International"}, "ResultsPayload": {"FinalReport": {"xmlnsxsd": "http://www.w3.org/2001/XMLSchema", "StagingId": "936288", "clinicalId": "937672", "xsinoNamespaceSchemaLocation": "http://integration.foundationmedicine.com/reporting/ClinicalReport.1.1.xsd", "Application": {"ApplicationSettings": {"ApplicationSetting": {"Name": "Statement", "Value": null}}}, "DemographicCorrectionDate": null, "ReportId": "ORD_1240190_01", "SampleName": "US1192709.01", "Version": "0", "Sample": {"FM_Id": "ORD_1240190_01", "SampleId": "US1192709.01", "BlockId": "nan", "TRFNumber": "ORD_1240190_01", "TestType": "FoundationOne Liquid  ", "SpecFormat": "Blood", "ReceivedDate": "2021_11_15", "processSites": {"processSite": [{"address": "150 Second St., 1st Floor, Cambridge, MA 02141", "cliaNumber": "22D2027531", "locationID": "1", "locationName": "Cambridge", "processID": "1", "processName": "Extracted DNA"}, {"address": "150 Second St., 1st Floor, Cambridge, MA 02141", "cliaNumber": "22D2027531", "locationID": "1", "locationName": "Cambridge", "processID": "1", "processName": "LC"}]}, "TumorPurity": "Cannot Be Determined", "SpecimenLocation": "nan"}, "PMI": {"ReportId": "S110-89570", "MRN": "47543968", "FullName": "\u5f35\u744b\u8587", "FirstName": "Wei_Wei", "LastName": "Chang", "SubmittedDiagnosis": "Poorly differentiated carcinoma, Colon (Diagnosis from S110-96703)", "Gender": "Female", "DOB": "1981_07_02", "OrderingMD": "\u9673\u660e\u6643", "OrderingMDId": "16468", "Pathologist": "\u5468\u5fb7\u76c8", "CopiedPhysician1": null, "MedFacilName": "Taipei Veterans General Hospital", "MedFacilID": "205872", "SpecSite": "Blood", "CollDate": "2021_11_10", "ReceivedDate": "2021-11-26 00:00:00", "CountryOfOrigin": "TW", "TumorType": "Carcinoma, NOS"}, "PertinentNegatives": null, "Summaries": {"alterationCount": "15", "clinicalTrialCount": "10", "resistiveCount": "0", "sensitizingCount": "0"}, "VariantProperties": {"VariantProperty": [{"geneName": "ARID1A", "isVUS": "true", "variantName": "V1982I"}, {"geneName": "DDR1", "isVUS": "true", "variantName": "R649W"}, {"geneName": "IRS2", "isVUS": "true", "variantName": "A512T"}, {"geneName": "KMT2A (MLL)", "isVUS": "true", "variantName": "I3186T"}, {"geneName": "MSH3", "isVUS": "true", "variantName": "A58V"}, {"geneName": "POLE", "isVUS": "true", "variantName": "R1839C"}, {"geneName": "PTCH1", "isVUS": "true", "variantName": "R1303C"}, {"geneName": "SPEN", "isVUS": "true", "variantName": "G1286W"}]}, "priorTests": null, "Genes": {"Gene": [{"Name": "KRAS", "Include": "true", "Alterations": {"Alteration": {"Name": "A146V", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "A146V"}}, "Interpretation": "KRAS encodes a member of the RAS family of small GTPases. Activating mutations in RAS genes can cause uncontrolled cell proliferation and tumor formation (Pylayeva_Gupta et al., 2011; 21993244, Kahn et al., 1987; 3310850). KRAS alterations affecting amino acids G12, G13, Q22, P34, A59, Q61, and A146, as well as mutations G10_A11insG, G10_A11insAG (also reported as G10_A11dup and G12_G13insAG), A18D, L19F, D33E, G60_A66dup/E62_A66dup, E62K, R68S, and K117N have been characterized as activating and oncogenic (Akagi et al., 2007; 17150185, Bollag et al., 1996; 8955068, Buhrman et al., 2010; 20194776, Colicelli, 2004; 15367757, Edkins et al., 2006; 16969076, Feig and Cooper, 1988; 3043178, Gremer et al., 2011; 20949621, Janakiraman et al., 2010; 20570890, Kim et al., 2016; 27147599, Lukman et al., 2010; 20838576, Naguib et al., 2011; 21371307, Prior et al., 2012; 22589270, Priv\u00e9 et al., 1992; 1565661, Pylayeva_Gupta et al., 2011; 21993244, Scheffzek et al., 1997; 9219684, Scholl et al., 2009; 19490892, Smith et al., 2010; 20147967, Tyner et al., 2009; 19075190, Valencia et al., 1991; 2029511, White et al., 2016; 26854029, Wiest et al., 1994; 8058307, Kim et al., 2016; 27147599, Angeles et al., 2019; 31289513, Tong et al., 2014; 24642870, Loree et al., 2021; 34117033). KRAS mutations have been observed in 18% of tumor samples analyzed in the COSMIC database, including 53% of pancreatic, 45% of peritoneal, 32% of colorectal, 21% of small intestinal, 18% of biliary tract, and 15% of lung tumors (Jul 2021)(Tate et al., 2019; 30371878). Mutations in KRAS have been reported in 32_54% of colorectal cancer cases, with the G12C, G12V, and G13D mutations specifically identified in 7_11%, 26_32%, and 16_24% of cases, respectively (Lievre et al., 2006; 16618717, De Roock et al., 2011; 21163703, Huang et al., 2013; 24330663, Kosmidou et al., 2013; 24352906, Maus et al., 2014; 24331409, Peeters et al., 2013; 23182985). Additionally, an activating KRAS mutation has been reported in more than 80% of pancreatic adenocarcinomas, with the majority of mutations found at codon 12 (Feldmann et al., 2007; 17520196, Rachakonda et al., 2013; 23565280, Hruban et al., 1993; 8342602, Maitra et al., 2006; 16549325). KRAS mutations, particularly G12D, have been associated with decreased median survival time in patients with pancreatic ductal adenocarcinoma (Rachakonda et al., 2013; 23565280). KRAS mutation in lung adenocarcinoma has been correlated with disease progression, poorly differentiated tumors, and aggressive tumor behavior (NCCN NSCLC Guidelines, v4.2021)(Yip et al., 2013; 23392229, Rekhtman et al., 2013; 23619604, Scoccianti et al., 2012; 22267755). However, the prognostic value of KRAS mutation in lung adenocarcinoma may differ among ethnic groups and may depend upon the specific allelic variant present (T\u00edm\u00e1r, 2014; 24463346). Preclinical and clinical data suggest that KRAS mutations may predict clinical benefit from SHP2 inhibitors (Lu et al., 2019; 31068384, Mainardi et al., 2018; 29808006, Koczywas et al., 2021; AACR Abstract LB001, Brana et al., 2021; ASCO Abstract 3005, Bendell et al., 2020; EORTC_NCI_AACR Abstract 5). A Phase 1 study of RMC_4630 for relapsed/refractory solid tumors reported a DCR of 58% (23/40) for patients with NSCLC and KRAS mutations and a DCR of 75% (12/16) for patients with NSCLC and KRAS G12C mutations (Koczywas et al., 2021; AACR Abstract LB001). Interim results from a Phase 1/2 study of RMC_4630 plus cobimetinib reported tumor reduction in 3 of 8 patients with KRAS_mutated colorectal cancer (Bendell et al., 2020; EORTC_NCI_AACR Abstract 5). Preclinical evidence suggests that KRAS activation may predict sensitivity to MEK inhibitors, such as trametinib, binimetinib, cobimetinib, and selumetinib (Nakano et al., 1984; 6320174, Pylayeva_Gupta et al., 2011; 21993244, Yamaguchi et al., 2011; 21523318, Watanabe et al., 2013; 23438367, Gilmartin et al., 2011; 21245089, Yeh et al., 2009; 19372556). Preclinical data suggest that KRAS mutation may confer sensitivity to SOS1 inhibitors (Hillig et al., 2019; 30683722, Hofmann et al., 2021; 32816843, Gerlach et al., 2020; AACR Abstract 1091). Phase 1 studies of the SOS1 inhibitor BI 1701963 alone or in combination with MEK inhibitors, KRAS G12C inhibitors, or irinotecan are recruiting for patients with solid tumors harboring KRAS mutations (Hofmann et al., 2021; AACR Abstract CT210, Gort et al., 2020; ASCO Abstract TPS3651). While clinical responses have been reported for patients with KRAS_mutated ovarian (Monk et al., 2020; 32822286, Farley et al., 2013; 23261356, Pejovic et al., 2015; Am J Clin Exp Obstet Gynecol 2:140_143, Slosberg et al., 2018; 29765547, Han et al., 2018; 29946554), cervical small cell neuroendocrine (Lyons et al., 2014; 26075998), or uterine cancer (Slosberg et al., 2018; 29765547) treated with MEK inhibitor monotherapy, multiple clinical trials have not demonstrated increased response rates for patients with KRAS_altered tumors including KRAS_mutated CRC (Tsimberidou et al., 2013; ASCO Abstract e22086, Infante et al., 2012; 22805291, Zimmer et al., 2014; 24947927, Bennouna et al., 2011; 20127139, Weekes et al., 2013; 23434733), pancreatic cancer (Van Laethem et al., 2017; 27975152, Infante et al., 2014; 24915778, Van Cutsem et al., 2018; 29756206), and NSCLC (Blumenschein et al., 2015; 25722381, Leijen et al., 2012; 22767668, Zimmer et al., 2014; 24947927). A Phase 2 study of trametinib and uprosertib for patients with recurrent cervical cancer reported no responses for patients with KRAS_mutated (2/2 SDs) or KRAS_amplified (1/1 SD) cancer (Lui et al., 2019; 31118140). Clinical responses have been reported for combination treatment strategies including MEK inhibitors with PI3K or AKT inhibitors for patients with KRAS_mutated ovarian cancer (Spreafico et al., 2014; ASCO Abstract 5506, Juric et al., 2014; ASCO Abstract 9051, Banerji et al., 2014; ASCO Abstract e13559) and KRAS_mutated endometrioid adenocarcinoma (Shapiro et al., 2019; 31020608).", "Include": "true", "ClinicalTrialNote": "KRAS activating mutations or amplification may predict sensitivity to inhibitors of MAPK pathway components, including MEK inhibitors.", "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": {"ClinicalTrialLink": [{"nctId": "NCT04803318", "Include": "true"}, {"nctId": "NCT03498521", "Include": "true"}, {"nctId": "NCT03989115", "Include": "true"}, {"nctId": "NCT03284502", "Include": "true"}, {"nctId": "NCT04801966", "Include": "true"}, {"nctId": "NCT03905148", "Include": "true"}, {"nctId": "NCT02079740", "Include": "true"}, {"nctId": "NCT04111458", "Include": "true"}, {"nctId": "NCT02407509", "Include": "true"}, {"nctId": "NCT04800822", "Include": "true"}]}}}, "ReferenceLinks": null}, {"Name": "Blood Tumor Mutational Burden", "Include": "true", "Alterations": {"Alteration": {"Name": "00", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "00"}}, "Interpretation": "Blood tumor mutational burden (bTMB, also known as mutation load) is a measure of the number of somatic protein_coding base substitution and insertion/deletion mutations from circulating tumor DNA in blood. TMB is affected by a variety of causes, including exposure to mutagens such as ultraviolet light in melanoma (Pfeifer et al., 2005; 15748635, Hill et al., 2013; 23875803) and cigarette smoke in lung cancer (Pfeifer et al., 2002; 12379884, Rizvi et al., 2015; 25765070), treatment with temozolomide_based chemotherapy in glioma (Johnson et al., 2014; 24336570, Choi et al., 2018; 29452419), mutations in the proofreading domains of DNA polymerases encoded by the POLE and POLD1 genes (Cancer Genome Atlas Research Network, 2013; 23636398, Briggs and Tomlinson, 2013; 23447401, Heitzer and Tomlinson, 2014; 24583393, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919), and microsatellite instability (MSI) (Cancer Genome Atlas Research Network, 2013; 23636398, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919). High bTMB levels were not detected in this sample. It is unclear whether the bTMB levels in this sample would be predicted to be associated with sensitivity to PD_1_ or PD_L1_targeting immune checkpoint inhibitors, alone or in combination with other agents (Socinski et al., 2019 ESMO Abstract LBA83, Gandara et al., 2018; 30082870, Wang et al., 2019; 30816954, Aggarwal et al., 2020; 32102950, Rizvi et al., 2019; ASCO Abstract 9016). Depending on the clinical context, TMB testing of an alternate sample or by another methodology could be considered. Average bTMB levels in solid tumors other than NSCLC have not been evaluated (cBioPortal, COSMIC, PubMed, Mar 2021)(Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210, Tate et al., 2019; 30371878). Published data investigating the prognostic implications of TMB have mainly been investigated in the context of tissue TMB. In patients with NSCLC, increased TMB is associated with higher tumor grade and poor prognosis (Xiao et al., 2016; 27009843), as well as with a decreased frequency of known driver mutations in EGFR, ALK, ROS1, or MET (1% of high_TMB samples each), but not BRAF (10.3%) or KRAS (9.4%) (Spigel et al., 2016; ASCO Abstract 9017). Although some studies have reported a lack of association between smoking and increased TMB in NSCLC (Schwartz et al., 2016; ASCO Abstract 8533, Xiao et al., 2016; 27009843, Shim et al., 2015; 26200269), several other large studies did find a strong link (Govindan et al., 2012; 22980976, Ding et al., 2008; 18948947, Imielinski et al., 2012; 22980975, Kim et al., 2014; 24323028). In CRC, elevated TMB is associated with a higher frequency of BRAF V600E driver mutations (Cancer Genome Atlas Network, 2012; 22810696, Stadler et al., 2016; 27022117) and with microsatellite instability (MSI) (George et al., 2016; ASCO Abstract 3587, Nagahashi et al., 2016; ASCO Abstract e15103, Stadler et al., 2016; 27022117), which in turn has been reported to correlate with better prognosis (Samowitz et al., 2001; 11535541, Elsaleh and Iacopetta, 2001; 12445368, Brueckl et al., 2003; 12820457, Guidoboni et al., 2001; 11438476, Gryfe et al., 2000; 10631274, Sinicrope et al., 2006; 16952542, Guastadisegni et al., 2010; 20627535, Laghi and Malesci, 2012; 22722556). Although increased TMB is associated with increased tumor grade in endometrioid endometrial carcinoma (Mehnert et al., 2016; 27159395, Cancer Genome Atlas Research Network., 2013; 23636398, Hussein et al., 2015; 25394778, Church et al., 2013; 23528559) and bladder cancer (Cazier et al., 2016; 24777035), it is also linked with improved prognosis in patients with these tumor types (Rosenberg et al., 2016; ASCO Abstract 104, Cancer Genome Atlas Research Network., 2013; 23636398). On the basis of clinical evidence in NSCLC and HSNCC, increased bTMB may be associated with greater sensitivity to immunotherapeutic agents, including anti_PD_L1 (Socinski et al., 2019 ESMO Abstract LBA83, Gandara et al., 2018; 30082870, Wang et al., 2019; 30816954, Li et al., 2020; ASCO Abstract 6511) and anti_PD_1 (Aggarwal et al., 2020; 32102950, Peters et al., 2019; AACR Abstract CT074) therapies. In NSCLC, multiple clinical trials have shown patients with higher bTMB derive clinical benefit from immune checkpoint inhibitors following single agent or combination treatments with either CTLA4 inhibitors or chemotherapy, with reported high bTMB cutpoints ranging from 6 to 16 Muts/Mb (Gandara et al., 2018; 30082870, Socinski et al., 2019 ESMO Abstract LBA83, Aggarwal et al. 2020; 32102950, Rizvi et al., 2019; ASCO Abstract 9016). In HNSCC, a Phase 3 trial showed that bTMB \u226516 Muts/Mb (approximate equivalency \u22658 Muts/Mb as measured by this assay) was associated with improved survival from treatment with a PD_L1 inhibitor alone or in combination with a CTLA_4 inhibitor (Li et al., 2020; ASCO Abstract 6511).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "GNAS", "Include": "true", "Alterations": {"Alteration": {"Name": "R201H", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "R201H"}}, "Interpretation": "GNAS encodes the alpha subunit of the stimulatory G protein (Gs_alpha) (Hayward et al., 1998; 9860993). Gs_alpha is a guanine_nucleotide binding protein (G protein) that is involved in hormonal regulation of adenylate cyclase (Hayward et al., 1998; 9860993). GNAS has been reported to be amplified in cancer (Gao et al., 2013; 23550210) and may be biologically relevant in this context (Zack et al., 2013; 24071852, Beroukhim et al., 2010; 20164920). GNAS alterations that have been shown to result in constitutive activation of adenylyl cyclase and an increase in cellular cAMP concentration (Masters et al., 1989; 2549064, Graziano and Gilman, 1989; 2549065, Jang and Juhnn, 2001; 11322485, Landis et al., 1989; 2549426, Tobar_Rubin et al., 2013; 23288949, Mariot et al., 2011; 20887824) are predicted to be activating. Mutations at R201 specifically are commonly associated with McCune_Albright syndrome, a disease that can co_occur with various cancers in patients with GNAS activating mutations (Weinstein et al., 1991; 1944469, Collins et al., 2003; 12970318, Nault et al., 2012; 21835143). The highest incidences of GNAS mutations have been reported in intraductal papillary mucinous neoplasms (40_66%)(Furukawa et al., 2011; 22355676, Wu et al., 2011; 21775669) and appendiceal mucinous neoplasms (50_72%)(Nishikawa et al., 2013; 23403822, Singhi et al., 2014; 24925222) as well as in tumors affecting the peritoneum (22%), pituitary gland (20%), bone (15%), pancreas (12%), and small intestine (12%)(COSMIC, 2021)(Tate et al., 2019; 30371878). Amplification of GNAS has been reported in ovarian epithelial carcinomas (12_30%)(Cancer Genome Atlas Research Network., 2011; 21720365, Kan et al., 2010; 20668451, Tominaga et al., 2010; 20537689), colorectal adenocarcinoma (9%)(Cancer Genome Atlas Network., 2012; 22810696), stomach adenocarcinoma (7%)(Cancer Genome Atlas Research Network., 2014; 25079317), lung adenocarcinoma (6.5%)(Cancer Genome Atlas Research Network., 2014; 25079552), breast invasive carcinoma (6.5%)(Cancer Genome Atlas Network., 2012; 23000897), pancreatic adenocarcinoma (6%)(Bio_Witkiewicz et al., 2015; 25855536), and sarcomas (5.8%)(cBio_Barretina et al., 2010; 20601955). GNAS mutations are rare in hematological malignancies generally (COSMIC, 2021)(Tate et al., 2019; 30371878, cBio_Lohr et al., 2014; 24434212, Chapman et al., 2011; 21430775). Activating GNAS mutations have been identified in gastrointestinal polyps in 75% (3/4) of patients with McCune_Albright syndrome (Zacharin et al., 2011; 21357941). Amplification of GNAS has been associated with shorter progression_free survival in patients with ovarian cancer (Kan et al., 2010; 20668451, Tominaga et al., 2010; 20537689), while activating GNAS mutations have been correlated with tumor progression and poor prognosis in patients with gastric cancer (Alakus et al., 2009; 20027678). There are no therapies targeted to GNAS mutation in cancer. However, there is limited data indicating that a patient with appendiceal adenocarcinoma and a GNAS mutation (R201H) benefited from trametinib for 4 months (Ang et al., 2017; 28868010). Additionally, a patient with GNAS_mutated Erdheim_Chester disease exhibited a PR following treatment with single_agent trametinib (Saunders et al., 2019; 31740567).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "MUTYH", "Include": "true", "Alterations": {"Alteration": {"Name": "splice site 892_2A>G", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "splice site 892_2A>G"}}, "Interpretation": "MUTYH (also known as MYH) encodes an enzyme involved in DNA base excision repair, and loss of function mutations in MUTYH result in increased rates of mutagenesis and promotion of tumorigenesis (David et al., 2007; 17581577). The two most frequently reported MUTYH loss of function mutations are G382D (also referred to as G396D) and Y165C (also referred to as Y179C) (Molatore et al., 2010; 19953527, Kundu et al., 2009; 19836313, D Agostino et al., 2010; 20418187, Hegde et al., 2014; 24310308, Aretz et al., 2013; 22872101). Numerous other MUTYH mutations have also been shown to result in loss of function (Molatore et al., 2010; 19953527, Kundu et al., 2009; 19836313, Ali et al., 2008; 18534194, D Agostino et al., 2010; 20418187). In general, somatic MUTYH mutations are infrequently reported across cancer types (COSMIC, 2021)(Tate et al., 2019; 30371878). Monoallelic MUTYH mutation occurs in 1_2% of the general population (Hegde et al., 2014; 24310308, Aretz et al., 2013; 22872101). There is conflicting data regarding the impact of monoallelic mutations on the risk of developing CRC (Win et al., 2014; 24444654, Lubbe et al., 2009; 19620482, Jones et al., 2009; 19394335). Patients with MUTYH_mutant CRC were reported to have significantly improved overall survival compared to patients without MUTYH mutation (Nielsen et al., 2010; 21044966). There are no therapies or clinical trials available to address MUTYH alterations in cancer. One or more of the MUTYH variants observed here has been described in the ClinVar database as a likely pathogenic or pathogenic germline mutation (by an expert panel or multiple submitters) associated with MUTYH_associated polyposis (ClinVar, Sep 2021)(Landrum et al., 2018; 29165669). Follow_up germline testing would be needed to distinguish whether the finding in this patient is somatic or germline. Germline biallelic MUTYH mutation causes MUTYH_associated polyposis (also known as MYH_associated polyposis or MAP), an autosomal recessive condition characterized by multiple colorectal adenomas and increased lifetime risk of colorectal cancer (CRC) (Hegde et al., 2014; 24310308, Sampson et al., 2003; 12853198, Sieber et al., 2003; 12606733, Al_Tassan et al., 2002; 11818965). MAP accounts for approximately 0.7% of all CRC cases and 2% of early_onset CRC cases (Hegde et al., 2014; 24310308). In contrast to CRC, the role of MUTYH mutation in the context of other cancer types is not well established (Rennert et al., 2012; 21952991, Zhang et al., 2006; 16492928, von der Th\u00fcsen et al., 2011; 21189386, Casper et al., 2014; 24420788, Smith et al., 2009; 20110747). Estimates for the prevalence of MAP in the general population range from 1:5,000_1:10,000 (Aretz et al., 2013; 22872101). Therefore, in the appropriate clinical context, germline testing of MUTYH is recommended.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "Microsatellite status", "Include": "true", "Alterations": {"Alteration": {"Name": "Cannot Be Determined", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "Cannot Be Determined"}}, "Interpretation": "Microsatellite instability (MSI) is a condition of genetic hypermutability that generates excessive amounts of short insertion/deletion mutations in the genome; it generally occurs at microsatellite DNA sequences and is caused by a deficiency in DNA mismatch repair (MMR) in the tumor (Kocarnik et al., 2015; 26337942). Defective MMR and consequent MSI occur as a result of genetic or epigenetic inactivation of one of the MMR pathway proteins, primarily MLH1, MSH2, MSH6, or PMS2 (You et al., 2010; 21081928, Bairwa et al., 2014; 24623249, Kocarnik et al., 2015; 26337942). The level of MSI in this sample could not be determined with confidence. Depending on the clinical context, MSI testing of an alternate sample or by another methodology could be considered. MSI_high (MSI_H) has been observed at high frequency in endometrial cancers (14_33%)(Santin et al., ASCO 2016; Abstract 414, Zighelboim et al., 2007; 17513808, Hampel et al., 2006; 16885385, Stelloo et al., 2016; 27006490, Kanopiene et al., 2014; 25458958, Black et al., 2006; 16549821, Nout et al., 2012; 22609107, Steinbakk et al., 2011; 21547578, Bilbao et al., 2010; 20005452), colorectal cancers (CRCs; 10_15%)(Guastadisegni et al., 2010; 20627535, Pawlik et al., 2004; 15528785, Kocarnik et al., 2015; 26337942, Cancer Genome Atlas Network., 2012; 22810696, Lal et al., 2015; 25949894), and gastric cancers (12_35%)(Hiyama et al., 2004; 15209621, Wu et al., 1998; 9537253, dos Santos et al., 1996; 8536886, Fang et al., 2013; 23555086) and at lower frequencies in many other tumor types, including esophageal (Hall et al., 2016; ASCO Gastrointestinal Cancer Symposium Abstract 528, Farris et al., 2011; 21422910), small bowel (Gingras et al., 2015; AACR Pancreatic Cancer Abstract PR06, Agaramet al., 2010; 20395525, Ruemmele et al., 2009; 19252434, Planck et al., 2003; 12627520, Hibi et al., 1995; 7775257, Muneyuki et al., 2000; 11117578), hepatobiliary (Zhang et al., 2005; 15918185, Chiappini et al., 2004; 14656944, Suto et al., 2001; 11223838, Momoi et al., 2001; 11580146, Liengswangwong et al., 2003; 14506736, Moy et al., 2015; 25680569, Yoshida et al., 2000; 11063221), prostate (Cheng et al., 2016; Genitourinary Cancers Symposium Abstract 251, Pritchard et al., 2014; 25255306, Azzouzi et al., 2007; 17233803, Burger et al., 2006; 16924473), and urinary tract carcinomas (Harper et al., 2015; USCAP Abstract 905, Bai et al., 2013; 23690119, Giedl et al., 2014; 25319978, Yamamoto et al., 2006; 16675567). In one study, MSI_H status was associated with a positive prognostic effect in patients with gastric cancer treated with surgery alone and a negative predictive effect in patients treated with chemotherapy (Smyth et al., 2015; ASCO Gastrointestinal Cancers Symposium Abstract 62). Data regarding the role of MSI_H on prognosis and survival in endometrial cancer are conflicting (Zighelboim et al., 2007; 17513808, Kanopiene et al., 2014; 25458958, Bilbao_Sieyro et al., 2014; 25026289, Mackay et al., 2010; 20304627, Steinbakk et al., 2011; 21547578, Arabi et al., 2009; 19275958, Black et al., 2006; 16549821). However, studies specifically analyzing early stage endometrial cancer have reported a correlation between MSI_H and decreased survival (Stelloo et al., 2016; 27006490, Mackay et al., 2010; 20304627, Nout et al., 2012; 22609107, Bilbao et al., 2010; 20005452), thereby suggesting that MSI_H predicts for poor prognosis in this subset of endometrial tumors. On the basis of prospective clinical evidence in multiple solid tumor types, microsatellite instability (MSI) and associated increased tumor mutational burden (TMB) (Jass, 2007; 17204026, Lal et al., 2015; 25949894) may predict sensitivity to immune checkpoint inhibitors, including the approved PD_1_targeting agents cemiplimab, dostarlimab, nivolumab (alone or in combination with ipilimumab), and pembrolizumab (Overman et al., 2017; 28734759, Overman et al., 2018; 29355075, Overman et al., 2019; ASCO Abstract 635, Lipson et al., 2013; 23169436, Le et al., 2015; 26028255, Rizvi et al., 2015; 25765070, Oaknin et al., 2020; 33001143) and PD_L1_targeting agents atezolizumab, avelumab, and durvalumab (Hochster et al., 2017; ASCO Abstract 673, Fleming et al., 2018; ASCO Abstract 5585, Bang et al., 2018; ASCO Abstract 92). As the MSI status of this tumor is unknown, the relevance of these therapeutic approaches is unclear. While approximately 80% of MSI_H tumors arise due to somatic inactivation of an MMR pathway protein, about 20% arise due to germline mutations in one of the MMR genes (Kocarnik et al., 2015; 26337942), which are associated with a condition known as Lynch syndrome (also known as hereditary nonpolyposis colorectal cancer or HNPCC) (Lynch et al., 2009; 19659756). Lynch syndrome leads to an increased risk of colorectal, endometrial, gastric, and other cancers (Lynch et al., 2009; 19659756, Pande et al., 2012; 22714864, Kastrinos and Syngal, 2007; 17920897) and has an estimated prevalence in the general population ranging from 1:600 to 1:2000 (Silva et al., 2009; 19466295, Sehgal et al., 2014; 24978665, de la Chapelle et al., 2005; 16136383). Therefore, in the appropriate clinical context, germline testing of MLH1, MSH2, MSH6, and PMS2 is recommended.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "TET2", "Include": "true", "Alterations": {"Alteration": {"Name": "Q232*", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "Q232*"}}, "Interpretation": "TET2 encodes a tumor suppressor involved in reversing DNA methylation marks, a process critical for proper gene regulation (Ito et al., 2010; 20639862, Guo et al., 2011; 21496894). Alterations such as seen here may disrupt TET2 function or expression (Iyer et al., 2009; 19411852, Ko et al., 2010; 21057493, Yang et al., 2013; 22391558, Hu et al., 2013; 24315485, Wang et al., 2015; 25601757). TET2 alterations have been reported at relatively low frequencies in solid tumors and are more prevalent in hematological malignancies (cBioPortal, Jan 2021)(Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210). Published data investigating the prognostic implications of TET2 alterations in solid tumors are limited (PubMed, Jan 2021). There are no targeted therapies available to address genomic alterations in TET2 in solid tumors. Variants seen in this gene have been reported to occur in clonal hematopoiesis (CH), an age_related process in which hematopoietic stem cells acquire somatic mutations that allow for clonal expansion (Jaiswal et al., 2014; 25426837, Genovese et al., 2014; 25426838, Xie et al., 2014; 25326804, Acuna_Hidalgo et al., 2017; 28669404, Severson et al., 2018; 29678827, Fuster et al., 2018; 29420212). CH in this gene has been associated with increased mortality, risk of coronary heart disease, risk of ischemic stroke, and risk of secondary hematologic malignancy (Jaiswal et al., 2014; 25426837, Genovese et al., 2014; 25426838). Clinical management of patients with CH in this gene may include monitoring for hematologic changes and reduction of controllable risk factors for cardiovascular disease (Steensma., 2018; 30504320). Comprehensive genomic profiling of solid tumors detects nontumor alterations that are due to CH (Severson et al., 2018; 29678827, Chabon et al., 2020; 32269342, Razavi et al., 2019; 31768066). Patient_matched peripheral blood mononuclear cell sequencing is required to conclusively determine if this alteration is present in tumor or is secondary to CH.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "Tumor Fraction", "Include": "true", "Alterations": {"Alteration": {"Name": "Cannot Be Determined", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "Cannot Be Determined"}}, "Interpretation": "Tumor fraction provides an estimate of the percentage of ctDNA present in a cell_free DNA (cfDNA) sample. The tumor fraction estimate for this sample is based on the observed level of aneuploid instability. The tumor fraction algorithm utilized for FoundationOne Liquid CDx uses the allele frequencies of approximately 1,000 single_nucleotide polymorphism (SNP) sites across the genome. Unlike the maximum somatic allele frequency (MSAF) method of estimating ctDNA content (Li et al., 2019; 31602320), the tumor fraction metric does not take into account the allele frequency of individual variants but rather produces a more holistic estimate of ctDNA content using data from across the genome. The amount of ctDNA detected may correlate with disease burden and response to therapy (Zhang et al., 2020; 32757294, Butler et al., 2019; 30833418). However, the tumor fraction estimate in this sample could not be determined with confidence. Detectible ctDNA levels have been reported in a variety of tumor types, with higher tumor fraction levels reported for patients with metastatic (Stage 4) tumors compared with patients with localized disease (Stages 1 to 3) (Bettegowda et al., 2014; 24553385). Elevated tumor fraction levels have been reported to be associated with worse prognosis in a variety of cancer types, including pancreatic cancer (Lapin et al., 2018; 30400802), Ewing sarcoma and osteosarcoma (Shulman et al., 2018; 30131550), prostate cancer (Choudhury et al., 2018; 30385733, Conteduca et al., 2019; ASCO abstract 5039), breast cancer (Stover et al., 2018; 29298117), leiomyosarcoma (Hemming et al., 2019; 30793095), esophageal cancer (Egyud et al., 2019; 31059681), colorectal cancer (Fan et al., 2017; 28187169), and gastrointestinal cancer (Vu et al., 2020; DOI: 10.1200/PO.19.00204). Specimens with high tumor fraction values have high circulating_tumor DNA (ctDNA) content, and thus higher sensitivity for identifying genomic alterations. Such specimens are at a lower risk of false negative results (Li et al., 2021; AACR Abstract 2231). However, if tumor fraction is not detected as high, it does not exclude the presence of disease burden or compromise the confidence of reported alterations. Tumor fraction levels currently have limited implications for diagnosis, surveillance, or therapy and should not be overinterpreted or compared from one blood draw to another. There are currently no targeted approaches to address specific tumor fraction levels. In the research setting, changes in tumor fraction estimates have been associated with treatment duration and clinical response and may be a useful indicator for future cancer management (Bronkhorst et al., 2019; 30923679, Raja et al., 2018; 30093454, Hrebien et al., 2019; 30860573, Conteduca et al., 2019; ASCO Abstract 5039, Choudhury et al., 2018; 30385733, Goodall et al., 2017; 28450425, Goldberg et al., 2018; 29330207).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}]}, "Trials": {"Trial": [{"Gene": "KRAS", "Alteration": "A146V", "Title": "Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors", "StudyPhase": "PHASE 2", "Target": "mTOR, FGFRs, KIT, PDGFRA, RET, VEGFRs, MEK", "Locations": "Guangzhou (China)", "NCTID": "NCT04803318", "Note": "KRAS activating mutations or amplification may predict sensitivity to inhibitors of MAPK pathway components, including MEK inhibitors.", "Include": "true"}, {"Gene": "KRAS", "Alteration": "A146V", "Title": "A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum_Based Chemotherapy in Patients With Cancer of Unknown Primary Site", "StudyPhase": "PHASE 2", "Target": "ALK, RET, SMO, AKTs, PARP, PD_L1, EGFR, VEGFA, MEK, BRAF, ERBB2, ERBB3, ROS1, TRKA, TRKB, TRKC", "Locations": "Fukuoka (Japan), Ehime (Japan), Seoul (Korea, Republic of), Aichi (Japan), Tokyo (Japan), Chiba (Japan), Bangkok (Thailand), Blacktown (Australia), St Leonards (Australia), Helsinki (Finland)", "NCTID": "NCT03498521", "Note": "KRAS activating mutations or amplification may predict sensitivity to inhibitors of MAPK pathway components, including MEK inhibitors.", "Include": "true"}, {"Gene": "KRAS", "Alteration": "A146V", "Title": "Dose_Escalation and Dose_Expansion of RMC_4630 and Cobimetinib in Relapsed/Refractory Solid Tumors", "StudyPhase": "PHASE 1/2", "Target": "SHP2, MEK", "Locations": "Seoul (Korea, Republic of), Oregon, California, Colorado, Arizona, Wisconsin, Illinois", "NCTID": "NCT03989115", "Note": "KRAS activating mutations or amplification may predict sensitivity to inhibitors of MAPK pathway components, including MEK inhibitors.", "Include": "true"}, {"Gene": "KRAS", "Alteration": "A146V", "Title": "Cobimetinib and HM95573 in Patients With Locally Advanced or Metastatic Solid Tumors", "StudyPhase": "PHASE 1", "Target": "MEK, RAFs", "Locations": "Hwasun (Korea, Republic of), Pusan (Korea, Republic of), Seongnam (Korea, Republic of), Seoul (Korea, Republic of), Goyang_si (Korea, Republic of)", "NCTID": "NCT03284502", "Note": "KRAS activating mutations or amplification may predict sensitivity to inhibitors of MAPK pathway components, including MEK inhibitors.", "Include": "true"}, {"Gene": "KRAS", "Alteration": "A146V", "Title": "Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study", "StudyPhase": "PHASE null", "Target": "CDK4, CDK6, PI3K_alpha, PD_L1, MEK, PARP, PD_1, BRAF", "Locations": "Melbourne (Australia)", "NCTID": "NCT04801966", "Note": "KRAS activating mutations or amplification may predict sensitivity to inhibitors of MAPK pathway components, including MEK inhibitors.", "Include": "true"}, {"Gene": "KRAS", "Alteration": "A146V", "Title": "Study of the Safety and Pharmacokinetics of BGB_283 and PD_0325901 in Patients With Advanced or Refractory Solid Tumors", "StudyPhase": "PHASE 1/2", "Target": "RAFs, EGFR, MEK", "Locations": "Nedlands (Australia), Blacktown (Australia), Randwick (Australia), Melbourne (Australia), Texas", "NCTID": "NCT03905148", "Note": "KRAS activating mutations or amplification may predict sensitivity to inhibitors of MAPK pathway components, including MEK inhibitors.", "Include": "true"}, {"Gene": "KRAS", "Alteration": "A146V", "Title": "Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors", "StudyPhase": "PHASE 1/2", "Target": "BCL_W, BCL_XL, BCL2, MEK", "Locations": "Massachusetts", "NCTID": "NCT02079740", "Note": "KRAS activating mutations or amplification may predict sensitivity to inhibitors of MAPK pathway components, including MEK inhibitors.", "Include": "true"}, {"Gene": "KRAS", "Alteration": "A146V", "Title": "A Study to Test Different Doses of BI 1701963 Alone and Combined With Trametinib in Patients With Different Types of Advanced Cancer (Solid Tumours With KRAS Mutation)", "StudyPhase": "PHASE 1", "Target": "KRAS, SOS1, MEK", "Locations": "Frankfurt am Main (Germany), K\u00f6ln (Germany), Utrecht (Netherlands), Rotterdam (Netherlands), Massachusetts, Tennessee, Texas, North Carolina", "NCTID": "NCT04111458", "Note": "KRAS activating mutations or amplification may predict sensitivity to inhibitors of MAPK pathway components, including MEK inhibitors.", "Include": "true"}, {"Gene": "KRAS", "Alteration": "A146V", "Title": "Phase I Trial of RO5126766", "StudyPhase": "PHASE 1", "Target": "RAFs, MEK, mTOR", "Locations": "London (United Kingdom), Sutton (United Kingdom)", "NCTID": "NCT02407509", "Note": "KRAS activating mutations or amplification may predict sensitivity to inhibitors of MAPK pathway components, including MEK inhibitors.", "Include": "true"}, {"Gene": "KRAS", "Alteration": "A146V", "Title": "PF_07284892 in Participants With Advanced Solid Tumors", "StudyPhase": "PHASE 1", "Target": "SHP2, ROS1, ALK, BRAF, EGFR, MEK", "Locations": "California, Michigan, New York, Tennessee, Texas", "NCTID": "NCT04800822", "Note": "KRAS activating mutations or amplification may predict sensitivity to inhibitors of MAPK pathway components, including MEK inhibitors.", "Include": "true"}]}, "References": {"Reference": [{"number": "0", "ReferenceId": "21993244", "FullCitation": "Pylayeva_Gupta Y, et al. Nat. Rev. Cancer (2011) pmid: 21993244", "Include": "true"}, {"number": "1", "ReferenceId": "3310850", "FullCitation": "Kahn S, et al. Anticancer Res. () pmid: 3310850", "Include": "true"}, {"number": "2", "ReferenceId": "17150185", "FullCitation": "Akagi K, et al. Biochem. Biophys. Res. Commun. (2007) pmid: 17150185", "Include": "true"}, {"number": "3", "ReferenceId": "8955068", "FullCitation": "Bollag G, et al. J. Biol. Chem. (1996) pmid: 8955068", "Include": "true"}, {"number": "4", "ReferenceId": "20194776", "FullCitation": "Buhrman G, et al. Proc. Natl. Acad. Sci. U.S.A. (2010) pmid: 20194776", "Include": "true"}, {"number": "5", "ReferenceId": "15367757", "FullCitation": "Sci. STKE (2004) pmid: 15367757", "Include": "true"}, {"number": "6", "ReferenceId": "16969076", "FullCitation": "Edkins S, et al. Cancer Biol. Ther. (2006) pmid: 16969076", "Include": "true"}, {"number": "7", "ReferenceId": "3043178", "FullCitation": "Feig LA, et al. Mol. Cell. Biol. (1988) pmid: 3043178", "Include": "true"}, {"number": "8", "ReferenceId": "20949621", "FullCitation": "Gremer L, et al. Hum. Mutat. (2011) pmid: 20949621", "Include": "true"}, {"number": "9", "ReferenceId": "20570890", "FullCitation": "Janakiraman M, et al. Cancer Res. (2010) pmid: 20570890", "Include": "true"}, {"number": "10", "ReferenceId": "27147599", "FullCitation": "Kim E, et al. Cancer Discov (2016) pmid: 27147599", "Include": "true"}, {"number": "11", "ReferenceId": "20838576", "FullCitation": "Lukman S, et al. PLoS Comput. Biol. (2010) pmid: 20838576", "Include": "true"}, {"number": "12", "ReferenceId": "21371307", "FullCitation": "Naguib A, et al. J Mol Signal (2011) pmid: 21371307", "Include": "true"}, {"number": "13", "ReferenceId": "22589270", "FullCitation": "Prior IA, et al. Cancer Res. (2012) pmid: 22589270", "Include": "true"}, {"number": "14", "ReferenceId": "1565661", "FullCitation": "Priv\u00e9 GG, et al. Proc. Natl. Acad. Sci. U.S.A. (1992) pmid: 1565661", "Include": "true"}, {"number": "15", "ReferenceId": "9219684", "FullCitation": "Scheffzek K, et al. Science (1997) pmid: 9219684", "Include": "true"}, {"number": "16", "ReferenceId": "19490892", "FullCitation": "Scholl C, et al. Cell (2009) pmid: 19490892", "Include": "true"}, {"number": "17", "ReferenceId": "20147967", "FullCitation": "Smith G, et al. Br. J. Cancer (2010) pmid: 20147967", "Include": "true"}, {"number": "18", "ReferenceId": "19075190", "FullCitation": "Tyner JW, et al. Blood (2009) pmid: 19075190", "Include": "true"}, {"number": "19", "ReferenceId": "2029511", "FullCitation": "Valencia A, et al. Biochemistry (1991) pmid: 2029511", "Include": "true"}, {"number": "20", "ReferenceId": "26854029", "FullCitation": "White Y, et al. Nat Commun (2016) pmid: 26854029", "Include": "true"}, {"number": "21", "ReferenceId": "8058307", "FullCitation": "Wiest JS, et al. Oncogene (1994) pmid: 8058307", "Include": "true"}, {"number": "22", "ReferenceId": "31289513", "FullCitation": "Angeles AKJ, et al. Oncol Lett (2019) pmid: 31289513", "Include": "true"}, {"number": "23", "ReferenceId": "24642870", "FullCitation": "Tong JH, et al. Cancer Biol. Ther. (2014) pmid: 24642870", "Include": "true"}, {"number": "24", "ReferenceId": "34117033", "FullCitation": "Loree JM, et al. Clin Cancer Res (2021) pmid: 34117033", "Include": "true"}, {"number": "25", "ReferenceId": "30371878", "FullCitation": "Tate JG, et al. Nucleic Acids Res. (2019) pmid: 30371878", "Include": "true"}, {"number": "26", "ReferenceId": "16618717", "FullCitation": "Li\u00e8vre A, et al. Cancer Res. (2006) pmid: 16618717", "Include": "true"}, {"number": "27", "ReferenceId": "21163703", "FullCitation": "De Roock W, et al. Lancet Oncol. (2011) pmid: 21163703", "Include": "true"}, {"number": "28", "ReferenceId": "24330663", "FullCitation": "Huang CW, et al. BMC Cancer (2013) pmid: 24330663", "Include": "true"}, {"number": "29", "ReferenceId": "24352906", "FullCitation": "Kosmidou V, et al. Hum. Mutat. (2014) pmid: 24352906", "Include": "true"}, {"number": "30", "ReferenceId": "24331409", "FullCitation": "Maus MK, et al. Lung Cancer (2014) pmid: 24331409", "Include": "true"}, {"number": "31", "ReferenceId": "23182985", "FullCitation": "Peeters M, et al. J. Clin. Oncol. (2013) pmid: 23182985", "Include": "true"}, {"number": "32", "ReferenceId": "17520196", "FullCitation": "Feldmann G, et al. J Hepatobiliary Pancreat Surg (2007) pmid: 17520196", "Include": "true"}, {"number": "33", "ReferenceId": "23565280", "FullCitation": "Rachakonda PS, et al. PLoS ONE (2013) pmid: 23565280", "Include": "true"}, {"number": "34", "ReferenceId": "8342602", "FullCitation": "Hruban RH, et al. Am. J. Pathol. (1993) pmid: 8342602", "Include": "true"}, {"number": "35", "ReferenceId": "16549325", "FullCitation": "Maitra A, et al. Best Pract Res Clin Gastroenterol (2006) pmid: 16549325", "Include": "true"}, {"number": "36", "ReferenceId": "23392229", "FullCitation": "Yip PY, et al. J Thorac Oncol (2013) pmid: 23392229", "Include": "true"}, {"number": "37", "ReferenceId": "23619604", "FullCitation": "Rekhtman N, et al. Mod. Pathol. (2013) pmid: 23619604", "Include": "true"}, {"number": "38", "ReferenceId": "22267755", "FullCitation": "Scoccianti C, et al. Eur. Respir. J. (2012) pmid: 22267755", "Include": "true"}, {"number": "39", "ReferenceId": "24463346", "FullCitation": "Curr Opin Oncol (2014) pmid: 24463346", "Include": "true"}, {"number": "40", "ReferenceId": "31068384", "FullCitation": "Lu H, et al. Mol Cancer Ther (2019) pmid: 31068384", "Include": "true"}, {"number": "41", "ReferenceId": "29808006", "FullCitation": "Mainardi S, et al. Nat Med (2018) pmid: 29808006", "Include": "true"}, {"number": "42", "ReferenceId": "6320174", "FullCitation": "Nakano H, et al. Proc. Natl. Acad. Sci. U.S.A. (1984) pmid: 6320174", "Include": "true"}, {"number": "43", "ReferenceId": "21523318", "FullCitation": "Yamaguchi T, et al. Int. J. Oncol. (2011) pmid: 21523318", "Include": "true"}, {"number": "44", "ReferenceId": "23438367", "FullCitation": "Watanabe M, et al. Cancer Sci. (2013) pmid: 23438367", "Include": "true"}, {"number": "45", "ReferenceId": "21245089", "FullCitation": "Gilmartin AG, et al. Clin. Cancer Res. (2011) pmid: 21245089", "Include": "true"}, {"number": "46", "ReferenceId": "19372556", "FullCitation": "Yeh JJ, et al. Mol. Cancer Ther. (2009) pmid: 19372556", "Include": "true"}, {"number": "47", "ReferenceId": "30683722", "FullCitation": "Hillig RC, et al. Proc Natl Acad Sci U S A (2019) pmid: 30683722", "Include": "true"}, {"number": "48", "ReferenceId": "32816843", "FullCitation": "Hofmann MH, et al. Cancer Discov (2021) pmid: 32816843", "Include": "true"}, {"number": "49", "ReferenceId": "32822286", "FullCitation": "Monk BJ, et al. J Clin Oncol (2020) pmid: 32822286", "Include": "true"}, {"number": "50", "ReferenceId": "23261356", "FullCitation": "Farley J, et al. Lancet Oncol. (2013) pmid: 23261356", "Include": "true"}, {"number": "51", "ReferenceId": "29765547", "FullCitation": "Slosberg ED, et al. Oncotarget (2018) pmid: 29765547", "Include": "true"}, {"number": "52", "ReferenceId": "29946554", "FullCitation": "Han C, et al. Gynecol Oncol Rep (2018) pmid: 29946554", "Include": "true"}, {"number": "53", "ReferenceId": "26075998", "FullCitation": "Lyons YA, et al. Gynecol Oncol Rep (2014) pmid: 26075998", "Include": "true"}, {"number": "54", "ReferenceId": "22805291", "FullCitation": "Infante JR, et al. Lancet Oncol. (2012) pmid: 22805291", "Include": "true"}, {"number": "55", "ReferenceId": "24947927", "FullCitation": "Zimmer L, et al. Clin. Cancer Res. (2014) pmid: 24947927", "Include": "true"}, {"number": "56", "ReferenceId": "20127139", "FullCitation": "Bennouna J, et al. Invest New Drugs (2011) pmid: 20127139", "Include": "true"}, {"number": "57", "ReferenceId": "23434733", "FullCitation": "Weekes CD, et al. Clin. Cancer Res. (2013) pmid: 23434733", "Include": "true"}, {"number": "58", "ReferenceId": "27975152", "FullCitation": "Van Laethem JL, et al. Target Oncol (2017) pmid: 27975152", "Include": "true"}, {"number": "59", "ReferenceId": "24915778", "FullCitation": "Infante JR, et al. Eur. J. Cancer (2014) pmid: 24915778", "Include": "true"}, {"number": "60", "ReferenceId": "29756206", "FullCitation": "Van Cutsem E, et al. Int. J. Cancer (2018) pmid: 29756206", "Include": "true"}, {"number": "61", "ReferenceId": "25722381", "FullCitation": "Blumenschein GR, et al. Ann. Oncol. (2015) pmid: 25722381", "Include": "true"}, {"number": "62", "ReferenceId": "22767668", "FullCitation": "Leijen S, et al. Clin. Cancer Res. (2012) pmid: 22767668", "Include": "true"}, {"number": "63", "ReferenceId": "31118140", "FullCitation": "Liu JF, et al. Gynecol. Oncol. (2019) pmid: 31118140", "Include": "true"}, {"number": "64", "ReferenceId": "31020608", "FullCitation": "Shapiro GI, et al. Invest New Drugs (2019) pmid: 31020608", "Include": "true"}, {"number": "65", "ReferenceId": "17581577", "FullCitation": "David SS, et al. Nature (2007) pmid: 17581577", "Include": "true"}, {"number": "66", "ReferenceId": "19953527", "FullCitation": "Molatore S, et al. Hum. Mutat. (2010) pmid: 19953527", "Include": "true"}, {"number": "67", "ReferenceId": "19836313", "FullCitation": "Kundu S, et al. DNA Repair (Amst.) (2009) pmid: 19836313", "Include": "true"}, {"number": "68", "ReferenceId": "20418187", "FullCitation": "D Agostino VG, et al. DNA Repair (Amst.) (2010) pmid: 20418187", "Include": "true"}, {"number": "69", "ReferenceId": "24310308", "FullCitation": "Hegde M, et al. Genet. Med. (2014) pmid: 24310308", "Include": "true"}, {"number": "70", "ReferenceId": "22872101", "FullCitation": "Aretz S, et al. Eur. J. Hum. Genet. (2013) pmid: 22872101", "Include": "true"}, {"number": "71", "ReferenceId": "18534194", "FullCitation": "Ali M, et al. Gastroenterology (2008) pmid: 18534194", "Include": "true"}, {"number": "72", "ReferenceId": "24444654", "FullCitation": "Win AK, et al. Gastroenterology (2014) pmid: 24444654", "Include": "true"}, {"number": "73", "ReferenceId": "19620482", "FullCitation": "Lubbe SJ, et al. J. Clin. Oncol. (2009) pmid: 19620482", "Include": "true"}, {"number": "74", "ReferenceId": "19394335", "FullCitation": "Jones N, et al. Gastroenterology (2009) pmid: 19394335", "Include": "true"}, {"number": "75", "ReferenceId": "21044966", "FullCitation": "Nielsen M, et al. J. Natl. Cancer Inst. (2010) pmid: 21044966", "Include": "true"}, {"number": "76", "ReferenceId": "29165669", "FullCitation": "Landrum MJ, et al. Nucleic Acids Res. (2018) pmid: 29165669", "Include": "true"}, {"number": "77", "ReferenceId": "12853198", "FullCitation": "Sampson JR, et al. Lancet (2003) pmid: 12853198", "Include": "true"}, {"number": "78", "ReferenceId": "12606733", "FullCitation": "Sieber OM, et al. N. Engl. J. Med. (2003) pmid: 12606733", "Include": "true"}, {"number": "79", "ReferenceId": "11818965", "FullCitation": "Al_Tassan N, et al. Nat. Genet. (2002) pmid: 11818965", "Include": "true"}, {"number": "80", "ReferenceId": "21952991", "FullCitation": "Rennert G, et al. Cancer (2012) pmid: 21952991", "Include": "true"}, {"number": "81", "ReferenceId": "16492928", "FullCitation": "Zhang Y, et al. Cancer Epidemiol. Biomarkers Prev. (2006) pmid: 16492928", "Include": "true"}, {"number": "82", "ReferenceId": "21189386", "FullCitation": "von der Th\u00fcsen JH, et al. J. Clin. Oncol. (2011) pmid: 21189386", "Include": "true"}, {"number": "83", "ReferenceId": "24420788", "FullCitation": "Casper M, et al. Fam. Cancer (2014) pmid: 24420788", "Include": "true"}, {"number": "84", "ReferenceId": "20110747", "FullCitation": "Smith LM, et al. Pancreatology (2009) pmid: 20110747", "Include": "true"}, {"number": "85", "ReferenceId": "31602320", "FullCitation": "Li G, et al. J Gastrointest Oncol (2019) pmid: 31602320", "Include": "true"}, {"number": "86", "ReferenceId": "32757294", "FullCitation": "Zhang EW, et al. Cancer (2020) pmid: 32757294", "Include": "true"}, {"number": "87", "ReferenceId": "30833418", "FullCitation": "Butler TM, et al. Cold Spring Harb Mol Case Stud (2019) pmid: 30833418", "Include": "true"}, {"number": "88", "ReferenceId": "24553385", "FullCitation": "Bettegowda C, et al. Sci Transl Med (2014) pmid: 24553385", "Include": "true"}, {"number": "89", "ReferenceId": "30400802", "FullCitation": "Lapin M, et al. J Transl Med (2018) pmid: 30400802", "Include": "true"}, {"number": "90", "ReferenceId": "30131550", "FullCitation": "Shulman DS, et al. Br. J. Cancer (2018) pmid: 30131550", "Include": "true"}, {"number": "91", "ReferenceId": "30385733", "FullCitation": "Choudhury AD, et al. JCI Insight (2018) pmid: 30385733", "Include": "true"}, {"number": "92", "ReferenceId": "29298117", "FullCitation": "Stover DG, et al. J. Clin. Oncol. (2018) pmid: 29298117", "Include": "true"}, {"number": "93", "ReferenceId": "30793095", "FullCitation": "Hemming ML, et al. JCO Precis Oncol (2019) pmid: 30793095", "Include": "true"}, {"number": "94", "ReferenceId": "31059681", "FullCitation": "Egyud M, et al. Ann. Thorac. Surg. (2019) pmid: 31059681", "Include": "true"}, {"number": "95", "ReferenceId": "28187169", "FullCitation": "Fan G, et al. PLoS ONE (2017) pmid: 28187169", "Include": "true"}, {"number": "96", "ReferenceId": "30923679", "FullCitation": "Bronkhorst AJ, et al. Biomol Detect Quantif (2019) pmid: 30923679", "Include": "true"}, {"number": "97", "ReferenceId": "30093454", "FullCitation": "Raja R, et al. Clin. Cancer Res. (2018) pmid: 30093454", "Include": "true"}, {"number": "98", "ReferenceId": "30860573", "FullCitation": "Hrebien S, et al. Ann. Oncol. (2019) pmid: 30860573", "Include": "true"}, {"number": "99", "ReferenceId": "28450425", "FullCitation": "Goodall J, et al. Cancer Discov (2017) pmid: 28450425", "Include": "true"}, {"number": "100", "ReferenceId": "29330207", "FullCitation": "Goldberg SB, et al. Clin. Cancer Res. (2018) pmid: 29330207", "Include": "true"}, {"number": "101", "ReferenceId": "20639862", "FullCitation": "Ito S, et al. Nature (2010) pmid: 20639862", "Include": "true"}, {"number": "102", "ReferenceId": "21496894", "FullCitation": "Guo JU, et al. Cell (2011) pmid: 21496894", "Include": "true"}, {"number": "103", "ReferenceId": "19411852", "FullCitation": "Iyer LM, et al. Cell Cycle (2009) pmid: 19411852", "Include": "true"}, {"number": "104", "ReferenceId": "21057493", "FullCitation": "Ko M, et al. Nature (2010) pmid: 21057493", "Include": "true"}, {"number": "105", "ReferenceId": "22391558", "FullCitation": "Yang H, et al. Oncogene (2013) pmid: 22391558", "Include": "true"}, {"number": "106", "ReferenceId": "24315485", "FullCitation": "Hu L, et al. Cell (2013) pmid: 24315485", "Include": "true"}, {"number": "107", "ReferenceId": "25601757", "FullCitation": "Wang Y, et al. Mol. Cell (2015) pmid: 25601757", "Include": "true"}, {"number": "108", "ReferenceId": "22588877", "FullCitation": "Cerami E, et al. Cancer Discov (2012) pmid: 22588877", "Include": "true"}, {"number": "109", "ReferenceId": "23550210", "FullCitation": "Gao J, et al. Sci Signal (2013) pmid: 23550210", "Include": "true"}, {"number": "110", "ReferenceId": "25426837", "FullCitation": "Jaiswal S, et al. N. Engl. J. Med. (2014) pmid: 25426837", "Include": "true"}, {"number": "111", "ReferenceId": "25426838", "FullCitation": "Genovese G, et al. N. Engl. J. Med. (2014) pmid: 25426838", "Include": "true"}, {"number": "112", "ReferenceId": "25326804", "FullCitation": "Xie M, et al. Nat. Med. (2014) pmid: 25326804", "Include": "true"}, {"number": "113", "ReferenceId": "28669404", "FullCitation": "Acuna_Hidalgo R, et al. Am. J. Hum. Genet. (2017) pmid: 28669404", "Include": "true"}, {"number": "114", "ReferenceId": "29678827", "FullCitation": "Severson EA, et al. Blood (2018) pmid: 29678827", "Include": "true"}, {"number": "115", "ReferenceId": "29420212", "FullCitation": "Fuster JJ, et al. Circ. Res. (2018) pmid: 29420212", "Include": "true"}, {"number": "116", "ReferenceId": "30504320", "FullCitation": "Hematology Am Soc Hematol Educ Program (2018) pmid: 30504320", "Include": "true"}, {"number": "117", "ReferenceId": "32269342", "FullCitation": "Chabon JJ, et al. Nature (2020) pmid: 32269342", "Include": "true"}, {"number": "118", "ReferenceId": "31768066", "FullCitation": "Razavi P, et al. Nat. Med. (2019) pmid: 31768066", "Include": "true"}, {"number": "119", "ReferenceId": "26337942", "FullCitation": "Kocarnik JM, et al. Gastroenterol Rep (Oxf) (2015) pmid: 26337942", "Include": "true"}, {"number": "120", "ReferenceId": "21081928", "FullCitation": "You JF, et al. Br. J. Cancer (2010) pmid: 21081928", "Include": "true"}, {"number": "121", "ReferenceId": "24623249", "FullCitation": "Bairwa NK, et al. Methods Mol. Biol. (2014) pmid: 24623249", "Include": "true"}, {"number": "122", "ReferenceId": "17513808", "FullCitation": "Zighelboim I, et al. J. Clin. Oncol. (2007) pmid: 17513808", "Include": "true"}, {"number": "123", "ReferenceId": "16885385", "FullCitation": "Hampel H, et al. Cancer Res. (2006) pmid: 16885385", "Include": "true"}, {"number": "124", "ReferenceId": "27006490", "FullCitation": "Stelloo E, et al. Clin. Cancer Res. (2016) pmid: 27006490", "Include": "true"}, {"number": "125", "ReferenceId": "25458958", "FullCitation": "Kanopien\u0117 D, et al. Medicina (Kaunas) (2014) pmid: 25458958", "Include": "true"}, {"number": "126", "ReferenceId": "16549821", "FullCitation": "Black D, et al. J. Clin. Oncol. (2006) pmid: 16549821", "Include": "true"}, {"number": "127", "ReferenceId": "22609107", "FullCitation": "Nout RA, et al. Gynecol. Oncol. (2012) pmid: 22609107", "Include": "true"}, {"number": "128", "ReferenceId": "21547578", "FullCitation": "Steinbakk A, et al. Cell Oncol (Dordr) (2011) pmid: 21547578", "Include": "true"}, {"number": "129", "ReferenceId": "20005452", "FullCitation": "Bilbao C, et al. Int. J. Radiat. Oncol. Biol. Phys. (2010) pmid: 20005452", "Include": "true"}, {"number": "130", "ReferenceId": "20627535", "FullCitation": "Guastadisegni C, et al. Eur. J. Cancer (2010) pmid: 20627535", "Include": "true"}, {"number": "131", "ReferenceId": "15528785", "FullCitation": "Pawlik TM, et al. Dis. Markers (2004) pmid: 15528785", "Include": "true"}, {"number": "132", "ReferenceId": "22810696", "FullCitation": "Nature (2012) pmid: 22810696", "Include": "true"}, {"number": "133", "ReferenceId": "25949894", "FullCitation": "Lal N, et al. Oncoimmunology (2015) pmid: 25949894", "Include": "true"}, {"number": "134", "ReferenceId": "15209621", "FullCitation": "Hiyama T, et al. J. Gastroenterol. Hepatol. (2004) pmid: 15209621", "Include": "true"}, {"number": "135", "ReferenceId": "9537253", "FullCitation": "Wu MS, et al. Cancer Res. (1998) pmid: 9537253", "Include": "true"}, {"number": "136", "ReferenceId": "8536886", "FullCitation": "dos Santos NR, et al. Gastroenterology (1996) pmid: 8536886", "Include": "true"}, {"number": "137", "ReferenceId": "23555086", "FullCitation": "Fang WL, et al. Biomed Res Int (2013) pmid: 23555086", "Include": "true"}, {"number": "138", "ReferenceId": "21422910", "FullCitation": "Farris AB, et al. Am. J. Surg. Pathol. (2011) pmid: 21422910", "Include": "true"}, {"number": "139", "ReferenceId": "20395525", "FullCitation": "Agaram NP, et al. Am. J. Clin. Pathol. (2010) pmid: 20395525", "Include": "true"}, {"number": "140", "ReferenceId": "19252434", "FullCitation": "Ruemmele P, et al. Am. J. Surg. Pathol. (2009) pmid: 19252434", "Include": "true"}, {"number": "141", "ReferenceId": "12627520", "FullCitation": "Planck M, et al. Cancer (2003) pmid: 12627520", "Include": "true"}, {"number": "142", "ReferenceId": "7775257", "FullCitation": "Hibi K, et al. Jpn. J. Cancer Res. (1995) pmid: 7775257", "Include": "true"}, {"number": "143", "ReferenceId": "11117578", "FullCitation": "Muneyuki T, et al. Dig. Dis. Sci. (2000) pmid: 11117578", "Include": "true"}, {"number": "144", "ReferenceId": "15918185", "FullCitation": "Zhang SH, et al. World J. Gastroenterol. (2005) pmid: 15918185", "Include": "true"}, {"number": "145", "ReferenceId": "14656944", "FullCitation": "Chiappini F, et al. Carcinogenesis (2004) pmid: 14656944", "Include": "true"}, {"number": "146", "ReferenceId": "11223838", "FullCitation": "Suto T, et al. J Surg Oncol (2001) pmid: 11223838", "Include": "true"}, {"number": "147", "ReferenceId": "11580146", "FullCitation": "Momoi H, et al. J. Hepatol. (2001) pmid: 11580146", "Include": "true"}, {"number": "148", "ReferenceId": "14506736", "FullCitation": "Liengswangwong U, et al. Int. J. Cancer (2003) pmid: 14506736", "Include": "true"}, {"number": "149", "ReferenceId": "25680569", "FullCitation": "Moy AP, et al. Virchows Arch. (2015) pmid: 25680569", "Include": "true"}, {"number": "150", "ReferenceId": "11063221", "FullCitation": "Yoshida T, et al. J. Gastroenterol. (2000) pmid: 11063221", "Include": "true"}, {"number": "151", "ReferenceId": "25255306", "FullCitation": "Pritchard CC, et al. Nat Commun (2014) pmid: 25255306", "Include": "true"}, {"number": "152", "ReferenceId": "17233803", "FullCitation": "Azzouzi AR, et al. BJU Int. (2007) pmid: 17233803", "Include": "true"}, {"number": "153", "ReferenceId": "16924473", "FullCitation": "Burger M, et al. J. Mol. Med. (2006) pmid: 16924473", "Include": "true"}, {"number": "154", "ReferenceId": "23690119", "FullCitation": "Bai S, et al. Am. J. Clin. Pathol. (2013) pmid: 23690119", "Include": "true"}, {"number": "155", "ReferenceId": "25319978", "FullCitation": "Giedl J, et al. Am. J. Clin. Pathol. (2014) pmid: 25319978", "Include": "true"}, {"number": "156", "ReferenceId": "16675567", "FullCitation": "Yamamoto Y, et al. Clin. Cancer Res. (2006) pmid: 16675567", "Include": "true"}, {"number": "157", "ReferenceId": "25026289", "FullCitation": "Bilbao_Sieyro C, et al. Oncotarget (2014) pmid: 25026289", "Include": "true"}, {"number": "158", "ReferenceId": "20304627", "FullCitation": "Mackay HJ, et al. Eur. J. Cancer (2010) pmid: 20304627", "Include": "true"}, {"number": "159", "ReferenceId": "19275958", "FullCitation": "Arabi H, et al. Gynecol. Oncol. (2009) pmid: 19275958", "Include": "true"}, {"number": "160", "ReferenceId": "17204026", "FullCitation": "Histopathology (2007) pmid: 17204026", "Include": "true"}, {"number": "161", "ReferenceId": "28734759", "FullCitation": "Overman MJ, et al. Lancet Oncol. (2017) pmid: 28734759", "Include": "true"}, {"number": "162", "ReferenceId": "29355075", "FullCitation": "Overman MJ, et al. J. Clin. Oncol. (2018) pmid: 29355075", "Include": "true"}, {"number": "163", "ReferenceId": "23169436", "FullCitation": "Lipson EJ, et al. Clin. Cancer Res. (2013) pmid: 23169436", "Include": "true"}, {"number": "164", "ReferenceId": "26028255", "FullCitation": "Le DT, et al. N. Engl. J. Med. (2015) pmid: 26028255", "Include": "true"}, {"number": "165", "ReferenceId": "25765070", "FullCitation": "Rizvi NA, et al. Science (2015) pmid: 25765070", "Include": "true"}, {"number": "166", "ReferenceId": "33001143", "FullCitation": "Oaknin A, et al. JAMA Oncol (2020) pmid: 33001143", "Include": "true"}, {"number": "167", "ReferenceId": "19659756", "FullCitation": "Lynch HT, et al. Clin. Genet. (2009) pmid: 19659756", "Include": "true"}, {"number": "168", "ReferenceId": "22714864", "FullCitation": "Pande M, et al. Fam. Cancer (2012) pmid: 22714864", "Include": "true"}, {"number": "169", "ReferenceId": "17920897", "FullCitation": "Kastrinos F, et al. Semin. Oncol. (2007) pmid: 17920897", "Include": "true"}, {"number": "170", "ReferenceId": "19466295", "FullCitation": "Silva FC, et al. Sao Paulo Med J (2009) pmid: 19466295", "Include": "true"}, {"number": "171", "ReferenceId": "24978665", "FullCitation": "Sehgal R, et al. Genes (Basel) (2014) pmid: 24978665", "Include": "true"}, {"number": "172", "ReferenceId": "16136383", "FullCitation": "Fam. Cancer (2005) pmid: 16136383", "Include": "true"}, {"number": "173", "ReferenceId": "9860993", "FullCitation": "Hayward BE, et al. Proc. Natl. Acad. Sci. U.S.A. (1998) pmid: 9860993", "Include": "true"}, {"number": "174", "ReferenceId": "24071852", "FullCitation": "Zack TI, et al. Nat. Genet. (2013) pmid: 24071852", "Include": "true"}, {"number": "175", "ReferenceId": "20164920", "FullCitation": "Beroukhim R, et al. Nature (2010) pmid: 20164920", "Include": "true"}, {"number": "176", "ReferenceId": "2549064", "FullCitation": "Masters SB, et al. J. Biol. Chem. (1989) pmid: 2549064", "Include": "true"}, {"number": "177", "ReferenceId": "2549065", "FullCitation": "Graziano MP, et al. J. Biol. Chem. (1989) pmid: 2549065", "Include": "true"}, {"number": "178", "ReferenceId": "11322485", "FullCitation": "Jang IS, et al. Exp. Mol. Med. (2001) pmid: 11322485", "Include": "true"}, {"number": "179", "ReferenceId": "2549426", "FullCitation": "Landis CA, et al. Nature (1989) pmid: 2549426", "Include": "true"}, {"number": "180", "ReferenceId": "23288949", "FullCitation": "Tobar_Rubin R, et al. J. Mol. Endocrinol. (2013) pmid: 23288949", "Include": "true"}, {"number": "181", "ReferenceId": "20887824", "FullCitation": "Mariot V, et al. Bone (2011) pmid: 20887824", "Include": "true"}, {"number": "182", "ReferenceId": "1944469", "FullCitation": "Weinstein LS, et al. N. Engl. J. Med. (1991) pmid: 1944469", "Include": "true"}, {"number": "183", "ReferenceId": "12970318", "FullCitation": "Collins MT, et al. J. Clin. Endocrinol. Metab. (2003) pmid: 12970318", "Include": "true"}, {"number": "184", "ReferenceId": "21835143", "FullCitation": "Nault JC, et al. J. Hepatol. (2012) pmid: 21835143", "Include": "true"}, {"number": "185", "ReferenceId": "22355676", "FullCitation": "Furukawa T, et al. Sci Rep (2011) pmid: 22355676", "Include": "true"}, {"number": "186", "ReferenceId": "21775669", "FullCitation": "Wu J, et al. Sci Transl Med (2011) pmid: 21775669", "Include": "true"}, {"number": "187", "ReferenceId": "23403822", "FullCitation": "Nishikawa G, et al. Br. J. Cancer (2013) pmid: 23403822", "Include": "true"}, {"number": "188", "ReferenceId": "24925222", "FullCitation": "Singhi AD, et al. Hum. Pathol. (2014) pmid: 24925222", "Include": "true"}, {"number": "189", "ReferenceId": "21720365", "FullCitation": "Nature (2011) pmid: 21720365", "Include": "true"}, {"number": "190", "ReferenceId": "20668451", "FullCitation": "Kan Z, et al. Nature (2010) pmid: 20668451", "Include": "true"}, {"number": "191", "ReferenceId": "20537689", "FullCitation": "Tominaga E, et al. Gynecol. Oncol. (2010) pmid: 20537689", "Include": "true"}, {"number": "192", "ReferenceId": "25079317", "FullCitation": "Nature (2014) pmid: 25079317", "Include": "true"}, {"number": "193", "ReferenceId": "25079552", "FullCitation": "Nature (2014) pmid: 25079552", "Include": "true"}, {"number": "194", "ReferenceId": "23000897", "FullCitation": "Nature (2012) pmid: 23000897", "Include": "true"}, {"number": "195", "ReferenceId": "25855536", "FullCitation": "Witkiewicz AK, et al. Nat Commun (2015) pmid: 25855536", "Include": "true"}, {"number": "196", "ReferenceId": "20601955", "FullCitation": "Barretina J, et al. Nat. Genet. (2010) pmid: 20601955", "Include": "true"}, {"number": "197", "ReferenceId": "24434212", "FullCitation": "Lohr JG, et al. Cancer Cell (2014) pmid: 24434212", "Include": "true"}, {"number": "198", "ReferenceId": "21430775", "FullCitation": "Chapman MA, et al. Nature (2011) pmid: 21430775", "Include": "true"}, {"number": "199", "ReferenceId": "21357941", "FullCitation": "Zacharin M, et al. J. Med. Genet. (2011) pmid: 21357941", "Include": "true"}, {"number": "200", "ReferenceId": "20027678", "FullCitation": "Alakus H, et al. World J. Gastroenterol. (2009) pmid: 20027678", "Include": "true"}, {"number": "201", "ReferenceId": "28868010", "FullCitation": "Ang C, et al. Case Rep Oncol () pmid: 28868010", "Include": "true"}, {"number": "202", "ReferenceId": "31740567", "FullCitation": "Saunders IM, et al. Oncologist (2019) pmid: 31740567", "Include": "true"}, {"number": "203", "ReferenceId": "15748635", "FullCitation": "Pfeifer GP, et al. Mutat. Res. (2005) pmid: 15748635", "Include": "true"}, {"number": "204", "ReferenceId": "23875803", "FullCitation": "Hill VK, et al. Annu Rev Genomics Hum Genet (2013) pmid: 23875803", "Include": "true"}, {"number": "205", "ReferenceId": "12379884", "FullCitation": "Pfeifer GP, et al. Oncogene (2002) pmid: 12379884", "Include": "true"}, {"number": "206", "ReferenceId": "24336570", "FullCitation": "Johnson BE, et al. Science (2014) pmid: 24336570", "Include": "true"}, {"number": "207", "ReferenceId": "29452419", "FullCitation": "Choi S, et al. Neuro_oncology (2018) pmid: 29452419", "Include": "true"}, {"number": "208", "ReferenceId": "23636398", "FullCitation": "Cancer Genome Atlas Research Network, et al. Nature (2013) pmid: 23636398", "Include": "true"}, {"number": "209", "ReferenceId": "23447401", "FullCitation": "Briggs S, et al. J. Pathol. (2013) pmid: 23447401", "Include": "true"}, {"number": "210", "ReferenceId": "24583393", "FullCitation": "Heitzer E, et al. Curr. Opin. Genet. Dev. (2014) pmid: 24583393", "Include": "true"}, {"number": "211", "ReferenceId": "25568919", "FullCitation": "Roberts SA, et al. Nat. Rev. Cancer (2014) pmid: 25568919", "Include": "true"}, {"number": "212", "ReferenceId": "30082870", "FullCitation": "Gandara DR, et al. Nat. Med. (2018) pmid: 30082870", "Include": "true"}, {"number": "213", "ReferenceId": "30816954", "FullCitation": "Wang Z, et al. JAMA Oncol (2019) pmid: 30816954", "Include": "true"}, {"number": "214", "ReferenceId": "32102950", "FullCitation": "Aggarwal C, et al. Clin. Cancer Res. (2020) pmid: 32102950", "Include": "true"}, {"number": "215", "ReferenceId": "27009843", "FullCitation": "Xiao D, et al. Oncotarget (2016) pmid: 27009843", "Include": "true"}, {"number": "216", "ReferenceId": "26200269", "FullCitation": "Shim HS, et al. J Thorac Oncol (2015) pmid: 26200269", "Include": "true"}, {"number": "217", "ReferenceId": "22980976", "FullCitation": "Govindan R, et al. Cell (2012) pmid: 22980976", "Include": "true"}, {"number": "218", "ReferenceId": "18948947", "FullCitation": "Ding L, et al. Nature (2008) pmid: 18948947", "Include": "true"}, {"number": "219", "ReferenceId": "22980975", "FullCitation": "Imielinski M, et al. Cell (2012) pmid: 22980975", "Include": "true"}, {"number": "220", "ReferenceId": "24323028", "FullCitation": "Kim Y, et al. J. Clin. Oncol. (2014) pmid: 24323028", "Include": "true"}, {"number": "221", "ReferenceId": "27022117", "FullCitation": "Stadler ZK, et al. J. Clin. Oncol. (2016) pmid: 27022117", "Include": "true"}, {"number": "222", "ReferenceId": "11535541", "FullCitation": "Samowitz WS, et al. Cancer Epidemiol. Biomarkers Prev. (2001) pmid: 11535541", "Include": "true"}, {"number": "223", "ReferenceId": "12445368", "FullCitation": "Elsaleh H, et al. Clin Colorectal Cancer (2001) pmid: 12445368", "Include": "true"}, {"number": "224", "ReferenceId": "12820457", "FullCitation": "Brueckl WM, et al. Anticancer Res. () pmid: 12820457", "Include": "true"}, {"number": "225", "ReferenceId": "11438476", "FullCitation": "Guidoboni M, et al. Am. J. Pathol. (2001) pmid: 11438476", "Include": "true"}, {"number": "226", "ReferenceId": "10631274", "FullCitation": "Gryfe R, et al. N. Engl. J. Med. (2000) pmid: 10631274", "Include": "true"}, {"number": "227", "ReferenceId": "16952542", "FullCitation": "Sinicrope FA, et al. Gastroenterology (2006) pmid: 16952542", "Include": "true"}, {"number": "228", "ReferenceId": "22722556", "FullCitation": "Laghi L, et al. Dig Dis (2012) pmid: 22722556", "Include": "true"}, {"number": "229", "ReferenceId": "27159395", "FullCitation": "Mehnert JM, et al. J. Clin. Invest. (2016) pmid: 27159395", "Include": "true"}, {"number": "230", "ReferenceId": "25394778", "FullCitation": "Hussein YR, et al. Mod. Pathol. (2015) pmid: 25394778", "Include": "true"}, {"number": "231", "ReferenceId": "23528559", "FullCitation": "Church DN, et al. Hum. Mol. Genet. (2013) pmid: 23528559", "Include": "true"}, {"number": "232", "ReferenceId": "24777035", "FullCitation": "Cazier JB, et al. Nat Commun (2014) pmid: 24777035", "Include": "true"}]}, "Signatures": {"Signature": {"ServerTime": "2021_11_22 19:50:39", "OpName": "Julie Tse, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director", "Text": "Julie Tse, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director"}}, "reportProperties": {"reportProperty": [{"identifier": "QualityControlMetrics", "key": "MedianCoverageValue", "value": "N/A"}, {"identifier": "AdditionalFindings", "key": "TumorMutationBurdenScore", "value": "Units Not Reported"}, {"identifier": "AdditionalFindings", "key": "MicrosatelliteStatusScore", "value": "0 fraction_unstable_loci"}, {"identifier": "AdditionalFindings", "key": "LossOfHeterozygosityScore", "value": "Units Not Reported"}, {"identifier": "AdditionalFindings", "key": "BloodTumorMutationalBurdenScore", "value": "0 Muts/Mb"}, {"identifier": "AdditionalFindings", "key": "TumorFractionScore", "value": "0%"}]}, "comments": null, "AAC": {"Amendmends": null}}, "variant_report": {"xmlns": "http://foundationmedicine.com/compbio/variant_report_external", "disease_ontology": "Unknown primary adenocarcinoma", "flowcell_analysis": "2000018856", "gender": "female", "pathology_diagnosis": "Adenocarcinoma", "pipeline_version": "v3.8.2", "purity_assessment": "25.0", "specimen": "ORD_1240190_01*US1192709.01", "study": "CLINICAL_F1LCDx", "test_request": "ORD_1240190_01", "test_type": "FoundationOneLiquidDx", "tissue_of_origin": "Blood", "xsischemaLocation": "http://foundationmedicine.com/compbio/variant_report_external http://integration.foundationmedicine.com/reporting/variant_report_external_2.2.xsd", "samples": {"sample": {"bait_set": "AB1", "name": "SQ_US1192709.01_1", "nucleic_acid_type": "DNA"}}, "quality_control": {"status": "Pass"}, "short_variants": {"short_variant": [{"allele_fraction": "0.5083", "cds_effect": "892_2A>G", "depth": "1619", "equivocal": "false", "functional_effect": "splice", "gene": "MUTYH", "percent_reads": "50.83", "position": "chr1:45797760", "protein_effect": "splice site 892_2A>G", "status": "likely", "strand": "_", "transcript": "NM_001048171", "dna_evidence": {"sample": "SQ_US1192709.01_1"}}, {"allele_fraction": "0.4877", "cds_effect": "5944G>A", "depth": "935", "equivocal": "false", "functional_effect": "missense", "gene": "ARID1A", "percent_reads": "48.77", "position": "chr1:27106333", "protein_effect": "V1982I", "status": "unknown", "strand": "+", "transcript": "NM_006015", "dna_evidence": {"sample": "SQ_US1192709.01_1"}}, {"allele_fraction": "0.003", "cds_effect": "602G>A", "depth": "2367", "equivocal": "false", "functional_effect": "missense", "gene": "GNAS", "percent_reads": "0.3", "position": "chr20:57484421", "protein_effect": "R201H", "status": "known", "strand": "+", "transcript": "NM_000516", "dna_evidence": {"sample": "SQ_US1192709.01_1"}}, {"allele_fraction": "0.0304", "cds_effect": "694C>T", "depth": "855", "equivocal": "false", "functional_effect": "nonsense", "gene": "TET2", "percent_reads": "3.04", "position": "chr4:106155793", "protein_effect": "Q232*", "status": "likely", "strand": "+", "transcript": "NM_001127208", "dna_evidence": {"sample": "SQ_US1192709.01_1"}}, {"allele_fraction": "0.0097", "cds_effect": "1945C>T", "depth": "1130", "equivocal": "false", "functional_effect": "missense", "gene": "DDR1", "percent_reads": "0.97", "position": "chr6:30865214", "protein_effect": "R649W", "status": "unknown", "strand": "+", "transcript": "NM_001954", "dna_evidence": {"sample": "SQ_US1192709.01_1"}}, {"allele_fraction": "0.5013", "cds_effect": "3856G>T", "depth": "1594", "equivocal": "false", "functional_effect": "missense", "gene": "SPEN", "percent_reads": "50.13", "position": "chr1:16256591", "protein_effect": "G1286W", "status": "unknown", "strand": "+", "transcript": "NM_015001", "dna_evidence": {"sample": "SQ_US1192709.01_1"}}, {"allele_fraction": "0.4961", "cds_effect": "5515C>T", "depth": "1034", "equivocal": "false", "functional_effect": "missense", "gene": "POLE", "percent_reads": "49.61", "position": "chr12:133215748", "protein_effect": "R1839C", "status": "unknown", "strand": "_", "transcript": "NM_006231", "dna_evidence": {"sample": "SQ_US1192709.01_1"}}, {"allele_fraction": "0.4701", "cds_effect": "1534G>A", "depth": "551", "equivocal": "false", "functional_effect": "missense", "gene": "IRS2", "percent_reads": "47.01", "position": "chr13:110436867", "protein_effect": "A512T", "status": "unknown", "strand": "_", "transcript": "NM_003749", "dna_evidence": {"sample": "SQ_US1192709.01_1"}}, {"allele_fraction": "0.5026", "cds_effect": "3907C>T", "depth": "1134", "equivocal": "false", "functional_effect": "missense", "gene": "PTCH1", "percent_reads": "50.26", "position": "chr9:98209631", "protein_effect": "R1303C", "status": "unknown", "strand": "_", "transcript": "NM_000264", "dna_evidence": {"sample": "SQ_US1192709.01_1"}}, {"allele_fraction": "0.5003", "cds_effect": "9557T>C", "depth": "1465", "equivocal": "false", "functional_effect": "missense", "gene": "MLL", "percent_reads": "50.03", "position": "chr11:118376173", "protein_effect": "I3186T", "status": "unknown", "strand": "+", "transcript": "NM_005933", "dna_evidence": {"sample": "SQ_US1192709.01_1"}}, {"allele_fraction": "0.0129", "cds_effect": "437C>T", "depth": "1788", "equivocal": "false", "functional_effect": "missense", "gene": "KRAS", "percent_reads": "1.29", "position": "chr12:25378561", "protein_effect": "A146V", "status": "known", "strand": "_", "transcript": "NM_004985", "dna_evidence": {"sample": "SQ_US1192709.01_1"}}, {"allele_fraction": "0.6061", "cds_effect": "173C>T", "depth": "358", "equivocal": "false", "functional_effect": "missense", "gene": "MSH3", "percent_reads": "60.61", "position": "chr5:79950719", "protein_effect": "A58V", "status": "unknown", "strand": "+", "transcript": "NM_002439", "dna_evidence": {"sample": "SQ_US1192709.01_1"}}]}, "copy_number_alterations": null, "rearrangements": null, "biomarkers": {"microsatellite_instability": {"status": "MSS"}, "tumor_mutation_burden": {"score": "0.0", "status": "low", "unit": "mutations_per_megabase"}}, "non_human_content": {"non_human": [{"organism": "HPV_16", "reads_per_million": "23", "status": "unknown", "dna_evidence": {"sample": "SQ_US1192709.01_1"}}, {"organism": "HHV_4", "reads_per_million": "33", "status": "unknown", "dna_evidence": {"sample": "SQ_US1192709.01_1"}}, {"organism": "HHV_8", "reads_per_million": "11", "status": "unknown", "dna_evidence": {"sample": "SQ_US1192709.01_1"}}]}}}}}